Oxford Biomedica (LON:OXB) Receives “Buy” Rating from Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of Oxford Biomedica (LON:OXB) in a research report sent to investors on Wednesday, Marketbeat.com reports. The firm currently has a GBX 950 price objective on the biopharmaceutical company’s stock.

Separately, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a research report on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of GBX 663.67.

Oxford Biomedica Price Performance

LON:OXB opened at GBX 637 on Wednesday. Oxford Biomedica has a twelve month low of GBX 232.50 and a twelve month high of GBX 952. The firm has a market capitalization of £769.95 million, a price-to-earnings ratio of -17.59 and a beta of 1.04. The company has a quick ratio of 1.67, a current ratio of 1.89 and a debt-to-equity ratio of 322.11. The stock’s 50 day moving average price is GBX 764.34 and its two-hundred day moving average price is GBX 661.22.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.